Novartis Ag (NYSE: NVS)
Novartis Ag Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Novartis Ag Company Info
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
News & Analysis
1 Magnificent Dividend Stock to Buy and Hold
The company's business went through some important changes last year.
2 Dividend Stocks to Buy and Hold Forever
These businesses look too strong to fail.
Top Commercial Real Estate Stocks
Commercial real estate stocks offer opportunities to get involved with some of the most interesting businesses in the world.
Investing in Top CRISPR Companies
These CRISPR stocks could be big winners for patient investors.
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer.
2 Green Flags and 1 Red Flag for Novartis Stock
The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.
3 Unstoppable Stocks to Buy and Hold for Decades
These stocks can be pillars for your long-term portfolio, and investing in all three offers excellent diversification.
2 Dividend Stocks to Buy and Hold Forever
These companies' prospects look secure.
Valuation
Podcast Episodes
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
What Happened With CAR-T Stocks in 2018
Here’s how CAR-T therapies did in their first full year on the market.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Washington Cuts a Check to Spark Healthcare Innovation
The 21st Century Cures Act ignites innovation with perks to biopharma and medical device makers. Also, Kite Pharma and Novartis prep plans to pitch their CAR-T cancer therapies to the FDA.
Earnings Transcripts
Novartis Ag (NVS) Q4 2023 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2023.
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2023.
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
NVS earnings call for the period ending June 30, 2023.
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.